<DOC>
	<DOCNO>NCT00397293</DOCNO>
	<brief_summary>This open label , multicenter Phase I/II study evaluate safety efficacy AT-101 combination topotecan relapsed/refractory small cell lung cancer</brief_summary>
	<brief_title>Study AT-101 Combination With Topotecan Relapsed/Refractory Small Cell Lung Cancer</brief_title>
	<detailed_description>Further Study Details provide Ascenta :</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Gossypol acetic acid</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Gossypol</mesh_term>
	<criteria>Histologically cytologically confirm small cell lung cancer ( SCLC ) . Mixed histology eligible . Progression disease one prior platinum contain chemotherapy regimen . Prior Regimen must contain irinotecan All patient must measurable disease . Patients may receive prior radiation therapy must recover treatmentrelated toxicity . ECOG performance status 01 Adequate hematologic function Adequate liver renal function Ability swallow oral medication Patients one prior regimen chemotherapy prior regimen contain platinum agent . Note : Patient stop prior therapy due toxicity le 2 cycle platinum base therapy would eligible phase II portion study . Prior chemotherapy regimen contain irinotecan . Active secondary malignancy . Unstable progressive brain metastasis . Prior history radiation therapy &gt; 25 % bone marrow . Uncontrolled concurrent illness include , limited : serious uncontrolled infection , symptomatic congestive heart failure ( CHF ) , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Failure recover toxicity relate prior therapy ( e.g. , surgery , radiation , chemotherapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>AT101</keyword>
	<keyword>AT-101</keyword>
	<keyword>cancer</keyword>
	<keyword>lung</keyword>
	<keyword>small-cell</keyword>
	<keyword>topotecan</keyword>
</DOC>